Trial reportBMC musculoskeletal disorders2025
Efficacy of direct adductor canal block in pain control and sparing opioid consumption after total knee arthroplasty: a randomized controlled trial.
Trial report in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe adductor canal block has been proven effective in controlling postoperative pain, but it requires additional space and manpower. In contrast, intraoperative or direct adductor canal block (D-ACB) is performed during the surgical procedure, eliminating additional time and cost. The purpose of this study was to evaluate the efficacy and safety of D-ACB. The authors hypothesized that adding D-ACB to periarticular injection (PAI) would help control postoperative pain and reduce opioid use after TKA without causing major side effects.
methodsAmong patients scheduled to undergo primary TKA from September 2023 to February 2024, 38 patients in the PAI-alone group and 40 patients in the D-ACB + PAI group were eligible for analysis. The PAI-alone group received only PAI, while the D-ACB + PAI group received an additional ACB intraoperatively. Pain VAS scores and opioid consumption from the day of operation to postoperative day 5 were collected. Neurotoxicity and cardiotoxicity were considered major adverse events and were monitored along with postoperative motor weakness and fall-down events.
resultsThe D-ACB + PAI group used less opioid compared to the PAI-alone group. No major adverse effects were observed in either group during the perioperative period.
conclusionIntraoperative direct ACB demonstrated an opioid-sparing effect when combined with PAI. By performing ACB intraoperatively, no additional space, cost, or manpower was required, and patients did not need an additional catheter for pain control. Direct ACB is a simple and safe procedure that can facilitate recovery after TKA.
trial registrationThis study was retrospectively registered at the Clinical Research Information Service on April 5, 2024 (KCT0009311).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.